Enliven Therapeutics (ELVN) Equity Ratio (2019 - 2026)
Enliven Therapeutics has reported Equity Ratio over the past 8 years, most recently at 0.98 for Q1 2026.
- Quarterly results put Equity Ratio at 0.98 for Q1 2026, up 2.36% from a year ago — trailing twelve months through Mar 2026 was 0.98 (up 2.36% YoY), and the annual figure for FY2025 was 0.97, up 1.48%.
- Equity Ratio reached 0.98 in Q1 2026 per ELVN's latest filing, up from 0.97 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.98 in Q1 2026 and bottomed at 1.15 in Q3 2022.
- Median Equity Ratio over the past 5 years was 0.95 (2024), compared with a mean of 0.52.
- The largest annual shift saw Equity Ratio crashed 224.09% in 2022 before it skyrocketed 255.14% in 2023.
- Over 5 years, Equity Ratio stood at 0.92 in 2022, then soared by 198.07% to 0.9 in 2023, then grew by 5.16% to 0.95 in 2024, then rose by 1.48% to 0.97 in 2025, then increased by 1.04% to 0.98 in 2026.
- Business Quant data shows Equity Ratio for ELVN at 0.98 in Q1 2026, 0.97 in Q4 2025, and 0.97 in Q3 2025.